Objective:

To investigate the behavior of JAK2 V617F-mutated blood cell clones before the development of overt myeloproliferative neoplasms (MPNs).

Approach:

• Study Design: Analyzed data from the Danish General Suburban Population Study, focusing on 67 individuals with detectable JAK2 V617F mutations over more than a decade.
• Mathematical Modeling: Estimated the expansion, stability, or decline of mutated hematopoietic stem cells using a mathematical model.

Key Findings:

• 47 of 67 participants showed significant growth advantage of mutated cells.
• 12 individuals exhibited significant clonal decline.
• 8 individuals showed no clear evidence of expansion.
• 37 participants were diagnosed with an MPN during follow-up.
• Participants who developed MPN had higher baseline JAK2 V617F allele burden and elevated hematological parameters.

Interpretation:

The presence of a JAK2 V617F mutation does not guarantee progression to MPN, and growth rate is not a perfect predictor of disease.

Limitations:

• The study's findings are based on a specific population and may not be generalizable.
• Additional factors influencing disease progression were not fully identified.

Conclusion:

Longitudinal molecular monitoring of JAK2 V617F allele burden, along with routine hematology parameters, may provide better insights into disease risk.

Sources:

• PNAS Study